Cargando…

An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for COVID-19, has caused an ongoing worldwide pandemic. Due to the rapid emergence of variants of concern (VOCs), novel vaccines and vaccination strategies are urgently needed. We developed an intranasal vaccine c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Li, Zhang, Haiwei, Li, Moxuan, Wu, Bihao, Zhang, Zhe, Gong, Rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708728/ https://www.ncbi.nlm.nih.gov/pubmed/36466882 http://dx.doi.org/10.3389/fimmu.2022.1005321

Ejemplares similares

SARS-CoV-2-Specific Adaptive Immunity in COVID-19 Survivors With Asthma
por: Chen, Li, et al.
Publicado: (2022)

A vaccine based on the yeast-expressed receptor-binding domain (RBD) elicits broad immune responses against SARS-CoV-2 variants
por: Liu, Yu, et al.
Publicado: (2022)

Combined Subcutaneous-Intranasal Immunization With Epitope-Based Antigens Elicits Binding and Neutralizing Antibody Responses in Serum and Mucosae Against PRRSV-2 and SARS-CoV-2
por: Fragoso-Saavedra, Mario, et al.
Publicado: (2022)

An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection
por: van der Ley, Peter A., et al.
Publicado: (2021)

Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020)
por: Kim, David S., et al.
Publicado: (2020)

Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates
por: Wu, Yixin, et al.
Publicado: (2022)

Intranasal Vaccination With Lipoproteins Confers Protection Against Pneumococcal Colonisation
por: Voß, Franziska, et al.
Publicado: (2018)

A nasal vaccine with inactivated whole-virion elicits protective mucosal immunity against SARS-CoV-2 in mice
por: Tokunoh, Nagisa, et al.
Publicado: (2023)

A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern
por: Ahmed, Shahbaz, et al.
Publicado: (2021)

Intranasal Vaccination with an Engineered Influenza Virus Expressing the Receptor Binding Subdomain of Botulinum Neurotoxin Provides Protective Immunity Against Botulism and Influenza
por: Li, Junwei, et al.
Publicado: (2015)

SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments
por: Canedo-Marroquín, Gisela, et al.
Publicado: (2020)

Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
por: Ma, Xiancai, et al.
Publicado: (2020)

Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2
por: An, Xingyue, et al.
Publicado: (2021)

Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents
por: Bošnjak, Berislav, et al.
Publicado: (2021)

Simultaneous Subcutaneous and Intranasal Administration of a CAF01-Adjuvanted Chlamydia Vaccine Elicits Elevated IgA and Protective Th1/Th17 Responses in the Genital Tract
por: Wern, Jeanette Erbo, et al.
Publicado: (2017)

Recombinant Mycobacterium paragordonae Expressing SARS-CoV-2 Receptor-Binding Domain as a Vaccine Candidate Against SARS-CoV-2 Infections
por: Kim, Byoung-Jun, et al.
Publicado: (2021)

Successive Site Translocating Inoculation Improved T Cell Responses Elicited by a DNA Vaccine Encoding SARS-CoV-2 S Protein
por: Tian, Xiangxiang, et al.
Publicado: (2022)

Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
por: Mao, Tianyang, et al.
Publicado: (2022)

Reduced binding activity of vaccine serum to omicron receptor-binding domain
por: Li, Mingzhi, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2
por: Nguyen, Khue G., et al.
Publicado: (2022)

Intranasal Immunization with Liposome-Displayed Receptor-Binding Domain Induces Mucosal Immunity and Protection against SARS-CoV-2
por: Huang, Wei-Chiao, et al.
Publicado: (2022)

Intranasal Lentiviral Vector-Mediated Antibody Delivery Confers Reduction of SARS-CoV-2 Infection in Elderly and Immunocompromised Mice
por: Du, Yue, et al.
Publicado: (2022)

Vaccination using mutated receptor binding domains of SARS-CoV-2: Evidence for partial immune escape but not serotype formation
por: Chang, Xinyue, et al.
Publicado: (2023)

Correction to “Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys”
por: Li, Heng, et al.
Publicado: (2021)

Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2
por: Pettini, Elena, et al.
Publicado: (2022)

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
por: Walls, Alexandra C., et al.
Publicado: (2021)

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
por: Walls, Alexandra C., et al.
Publicado: (2021)

An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in hamsters
por: Tabynov, Kairat, et al.
Publicado: (2023)

Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge
por: Guan, Xiaoqing, et al.
Publicado: (2023)

IL-33 Is Essential for Adjuvant Effect of Hydroxypropyl-β-Cyclodexrin on the Protective Intranasal Influenza Vaccination
por: Kobari, Shingo, et al.
Publicado: (2020)

Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models
por: Banihashemi, Seyed Reza, et al.
Publicado: (2022)

Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
por: Horvath, Dennis, et al.
Publicado: (2023)

SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans
por: Forgacs, David, et al.
Publicado: (2021)

SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity
por: Liu, Haolin, et al.
Publicado: (2022)

Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity
por: Scaglione, Antonella, et al.
Publicado: (2021)

A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding
por: Yang, Jing, et al.
Publicado: (2022)

Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters
por: Dalvie, Neil C., et al.
Publicado: (2021)

DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune response
por: Oktay, Esra, et al.
Publicado: (2023)

A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV
por: Lv, Zhengchao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_heu46v0jnvgf3vnvg7p8mt56eo